ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
企業コードADMA
会社名ADMA Biologics Inc
上場日Oct 17, 2013
最高経営責任者「CEO」Mr. Adam S. Grossman
従業員数677
証券種類Ordinary Share
決算期末Oct 17
本社所在地465 State Route 17
都市RAMSEY
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号07446
電話番号12014785552
ウェブサイトhttps://www.admabiologics.com/
企業コードADMA
上場日Oct 17, 2013
最高経営責任者「CEO」Mr. Adam S. Grossman
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし